Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Zhe Sun. (2023) Optimization of clobetasol propionate loaded niosomal gel for the treatment of psoriasis: Ex vivo and efficacy study. Journal of Dispersion Science and Technology 44:14, pages 2599-2609.
Read now
Read now
Mwangi J. Murage, Amanda Anderson, Susan A. Oliveria, Deborah Casso, Clement K. Ojeh, Talia M. Muram, Joseph F. Merola & Andre B. Araujo. (2018) Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity. Journal of Medical Economics 21:8, pages 745-754.
Read now
Read now
April W. Armstrong, Yang Zhao, Vivian Herrera, Yunfeng Li, Tim Bancroft, Michael Hull & Aylin Altan. (2017) Rethinking costs of psoriasis: 10% of patients account for nearly 40% of healthcare expenditures among enrollees with psoriasis in a U.S. health plan. Journal of Dermatological Treatment 28:7, pages 613-622.
Read now
Read now
Neil J. Korman, Yang Zhao, Yunfeng Li, Minlei Liao & Mary Helen Tran. (2015) Clinical symptoms and self-reported disease severity among patients with psoriasis – Implications for psoriasis management. Journal of Dermatological Treatment 26:6, pages 514-519.
Read now
Read now
Nicole C. Rouse, Michael E. Farhangian, Brooke Wehausen & Steven R. Feldman. (2015) The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 877-884.
Read now
Read now
Steven R Feldman, Chakkarin Burudpakdee, Smeet Gala, Merena Nanavaty & Usha G Mallya. (2014) The economic burden of psoriasis: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research 14:5, pages 685-705.
Read now
Read now
Hsien-Chang Lin, Pedro T. Lucas, Steven R. Feldman & Rajesh Balkrishnan. (2012) Medication use and associated health care outcomes and costs for patients with psoriasis in the United States. Journal of Dermatological Treatment 23:3, pages 196-202.
Read now
Read now
Andrew P. Yu, Jackson Tang, Jipan Xie, Eric Q. Wu, Shiraz R. Gupta, Yanjun Bao & Parvez M. Mulani. (2009) Economic burden of psoriasis compared to the general population and stratified by disease severity. Current Medical Research and Opinion 25:10, pages 2429-2438.
Read now
Read now
Yonghua Jing, Edward Kim, Min You, Andrei Pikalov & Quynh-Van Tran. (2009) Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. Journal of Medical Economics 12:2, pages 104-113.
Read now
Read now
Gino A Vena & Nicoletta Cassano. (2006) Emerging drugs for psoriasis. Expert Opinion on Emerging Drugs 11:4, pages 567-596.
Read now
Read now
Rotraut Mössner & Kristian Reich. (2006) Infliximab in the treatment of psoriasis. Expert Review of Dermatology 1:4, pages 515-526.
Read now
Read now
Articles from other publishers (32)
Huifang Liang, Brenna Kirk, Jennifer M. Polinski, Xiaomeng Yue, Ryan D. Kilpatrick & Joel M. Gelfand. (2023) Impact of Season and Other Factors on Initiation, Discontinuation, and Switching of Systemic Drug Therapy in Patients with Psoriasis: A Retrospective Study. JID Innovations 3:2, pages 100171.
Crossref
Crossref
Jashin J. Wu, Manasi Suryavanshi, David Davidson, Vardhaman Patel, Anuj Jain & Lauren Seigel. (2022) Economic Burden of Comorbidities in Patients with Psoriasis in the USA. Dermatology and Therapy 13:1, pages 207-219.
Crossref
Crossref
Khalid A. Alnaqbi, Suad Hannawi, Rajaie Namas, Waleed Alshehhi, Humeira Badsha & Jamal Al‐Saleh. (2022)
Consensus statements for evaluation and nonpharmacological Management of Psoriatic Arthritis in
UAE
. International Journal of Rheumatic Diseases 25:7, pages 725-732.
Crossref
Crossref
Havva Hilal AYVAZ. (2019) SIK GÖRÜLEN DERMATOLOJİK HASTALIKLARIN EKONOMİK YÜKÜTHE ECONOMIC BURDEN OF COMMON DERMATOLOGICAL DISEASES. ESTÜDAM Halk Sağlığı Dergisi 4, pages 35-51.
Crossref
Crossref
Wayne P. Gulliver, Shane Randell, Susanne Gulliver, Don Macdonald, Valerie Gregory, Sean Nagle & Olivier Chambenoit. (2018) An Investigation of Comorbid Disease and Health Service Utilization Among Patients With Moderate to Severe Psoriasis in Newfoundland and Labrador. Journal of Cutaneous Medicine and Surgery 23:1, pages 29-34.
Crossref
Crossref
Dongmun Ha, JeeYeon Lee, Dajeong Kim, In-Sun Oh, Eui-Kyung Lee & Ju-Young Shin. (2018) Healthcare utilization and medical expenditure of Korean psoriasis patients. Medicine 97:24, pages e11070.
Crossref
Crossref
Steven R. Feldman, Haijun Tian, Isabelle Gilloteau, Patrick Mollon & Meng Shu. (2017) Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database. BMC Health Services Research 17:1.
Crossref
Crossref
Hojatolah Karimipour, Neda Sayadi, Abdolali Shariati, Mohammad Hossein Haghighi & Reza Yaghoubi. (2017) The Effects of a Self-Care Program on Promoting Self-Care Behaviors in Patients with Psoriasis. Jundishapur Journal of Chronic Disease Care 6:3.
Crossref
Crossref
Sylwia Milaniuk, Aldona Pietrzak, Barbara Mosiewicz, Jerzy Mosiewicz & Kristian Reich. (2015) Influence of psoriasis on circulatory system function assessed in echocardiography. Archives of Dermatological Research 307:10, pages 855-861.
Crossref
Crossref
Steven R. Feldman, Yang Zhao, Lizheng Shi & Mary Helen Tran. (2015) Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis. Journal of Managed Care & Specialty Pharmacy 21:10, pages 874-888.
Crossref
Crossref
E.D. Dommasch, T. Li, O.I. Okereke, Y. Li, A.A. Qureshi & E. Cho. (2015) Risk of depression in women with psoriasis: a cohort study. British Journal of Dermatology 173:4, pages 975-980.
Crossref
Crossref
Jacqueline Vanderpuye-Orgle, Yang Zhao, Jackie Lu, Anshu Shrestha, Alison Sexton, Seth Seabury & Mark Lebwohl. (2015) Evaluating the economic burden of psoriasis in the United States. Journal of the American Academy of Dermatology 72:6, pages 961-967.e5.
Crossref
Crossref
L.-T. Kao, K.-H. Wang, H.-C. Lin, H.-C. Li, S. Yang & S.-D. Chung. (2015) Use of health care services by patients with psoriasis: a population-based study. British Journal of Dermatology 172:5, pages 1346-1352.
Crossref
Crossref
Steven R. Feldman, Yang Zhao, Lizheng Shi, Mary Helen Tran & Jackie Lu. (2015) Economic and Comorbidity Burden Among Moderate‐to‐Severe Psoriasis Patients with Comorbid Psoriatic Arthritis. Arthritis Care & Research 67:5, pages 708-717.
Crossref
Crossref
M. Le Moigne, A. Sommet, M. Lapeyre‐Mestre, R. Bourrel, L. Molinier, C. Paul & J‐.L. Montastruc. (2013) Healthcare cost impact of biological drugs compared with traditional systemic treatments in psoriasis: a cohort analysis in the French insurance database. Journal of the European Academy of Dermatology and Venereology 28:9, pages 1235-1244.
Crossref
Crossref
Kuan-Chen Chen, Sheng-Tzu Hung, Ching-Wen Wendy Yang, Tsen-Fang Tsai & Chao-Hsiun Tang. (2014) The economic burden of psoriatic diseases in Taiwan. Journal of Dermatological Science 75:3, pages 183-189.
Crossref
Crossref
Emmilia A. Dowlatshahi, Marlies Wakkee, Lidia R. Arends & Tamar Nijsten. (2014) The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis. Journal of Investigative Dermatology 134:6, pages 1542-1551.
Crossref
Crossref
Reginald Villacorta, Joel W. Hay & Andrew Messali. (2013) Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States. PharmacoEconomics 31:9, pages 823-839.
Crossref
Crossref
Alice B. Gottlieb & April W. Armstrong. (2013) Psoriasis Outcome Measures: A Report from the GRAPPA 2012 Annual Meeting. The Journal of Rheumatology 40:8, pages 1428-1433.
Crossref
Crossref
Noori Kim, Brienne Cressey, Michael Do, Rona Wang, Alice B. Gottlieb & Paul F. Lizzul. (2018) Impact of Accountable Care Organizations on Psoriasis Care. Psoriasis Forum 18a:4, pages 221-224.
Crossref
Crossref
K. Abuabara, H. Lee & A.B. Kimball. (2011) The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. British Journal of Dermatology 165:5, pages 1066-1073.
Crossref
Crossref
AB Kimball, A Guérin, M Tsaneva, AP Yu, EQ Wu, SR Gupta, Y Bao & PM Mulani. (2011) Economic burden of comorbidities in patients with psoriasis is substantial. Journal of the European Academy of Dermatology and Venereology 25:2, pages 157-163.
Crossref
Crossref
Wayne P. Gulliver, Don MacDonald, Neil Gladney, Reza Alaghehbandan, Proton Rahman & K. Adam Baker. (2011) Long-Term Prognosis and Comorbidities Associated with Psoriasis in the Newfoundland and Labrador Founder Population. Journal of Cutaneous Medicine and Surgery 15:1, pages 37-47.
Crossref
Crossref
E Christophers, JNWN Barker, CEM Griffiths, E Daudén, G Milligan, C Molta, R Sato & R Boggs. (2010) The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. Journal of the European Academy of Dermatology and Venereology 24:5, pages 548-554.
Crossref
Crossref
Ulrich Mrowietz & Kristian Reich. (2009) Ten years of infliximab: Its role in dermatology. European Journal of Pharmacology 623, pages S10-S16.
Crossref
Crossref
Aldona Pietrzak, Jacek Kądzielewski, Konrad Janowski, Jacek Roliński, Dorota Krasowska, Grażyna Chodorowska, Tomasz Paszkowski, Ewa Kapeć, Iwona Jastrzębska, Jacek Tabarkiewicz & Torello Lotti. (2009) Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity. International Journal of Dermatology 48:4, pages 379-387.
Crossref
Crossref
Marc Alexander Radtke & Matthias Augustin. (2008) Economic considerations in psoriasis management. Clinics in Dermatology 26:5, pages 424-431.
Crossref
Crossref
L. Wang, L. Yang, L. Gao, T. W. Gao, W. Li & Y. F. Liu. (2007) A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with psoriasis. International Journal of Immunogenetics 35:1, pages 45-49.
Crossref
Crossref
Ulrich Mrowietz, James T. Elder & Jonathan Barker. (2006) The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Archives of Dermatological Research 298:7, pages 309-319.
Crossref
Crossref
Kristian Reich & Ulrich Mrowietz. (2007) Treatment goals in psoriasis. JDDG 5:7, pages 566-574.
Crossref
Crossref
Oliver Schöffski, Matthias Augustin, Jörg Prinz, Karin Rauner, Erich Schubert, Stefan Sohn & Kristian Reich. (2007) Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: A multi-center study. JDDG 5:3, pages 209-218.
Crossref
Crossref
Ebere Akobundu, Jing Ju, Lisa Blatt & C Daniel Mullins. (2006) Cost-of-Illness Studies. PharmacoEconomics 24:9, pages 869-890.
Crossref
Crossref